<DOC>
	<DOC>NCT00460486</DOC>
	<brief_summary>The objective of this study is to investigate the immunogenicity and safety of FSME-IMMUN 0.5 ml in two age strata (stratum A: 16 to 49 years, stratum B: &gt; 50 years), with the first and second vaccinations being administered according to a rapid immunization schedule (12 Â± 2 days apart). The third vaccination will be administered approximately 6 months after the first dose.</brief_summary>
	<brief_title>Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis, Tick-Borne</mesh_term>
	<mesh_term>Formaldehyde</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male and female subjects will be eligible for participation in this study if they: Understand the nature of the study, agree to its provisions and provide written informed consent (assent if the subjects is under 18 years of age); Provide the written informed consent of their parents / legal guardian (if the subject is under 18 years of age); Are aged &gt;= 16 years (from the 16th birthday) at screening; Are clinically healthy, (i.e. the physician would have no reservations vaccinating with FSMEIMMUN 0.5 ml outside the scope of a clinical trial); Have a negative pregnancy test result at the first medical examination (if female and capable of bearing children); Agree to employ adequate birth control measures for the duration of the study (if female and capable of bearing children); Agree to keep a Subject Diary. Subjects will be excluded from participation in this study if they: Have a history of any previous tickborne encephalitis (TBE) vaccination; Have a history of TBE infection; Have a history of infection with or vaccination against other flaviviruses (e.g. dengue fever, yellow fever, Japanese Bencephalitis); Have a history of allergic reactions, in particular to one of the components of the vaccine; Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions; Have a known or suspected problem with drug or alcohol abuse (&gt; 4 liters wine / week or equivalent level of other alcoholic beverages); Have donated blood or plasma within 30 days of study entry; Have received a blood transfusion or immunoglobulins within 30 days of study entry; Are known to be HIV positive (an HIV test is not required specifically for the purpose of this study); Are simultaneously participating in another clinical trial including administration of an investigational product; Have participated in any other clinical study within six weeks prior to study entry; Are pregnant or breastfeeding (if female); Are a member of the team conducting this study or are in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator. Have received any other vaccination within two weeks prior to study entry.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>